Share Dilution

Sobi publishes the first quarter 2022 report

STOCKHOLM, April 28, 2022 /PRNewswire/ — Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the first quarter of 2022

January – March 2022

  • Total revenue 4,925 million Swedish crowns (3,661), +35%, +24% at constant exchange rates (CER)
  • Hematology revenue SEK 2,499m (1,877), +25% at constant exchange rates including Elocta® SEK 1,024 million (857), +15% at CER; Alprolix® SEK 419 million (413), -3% at CER; Doptelet® SEK 593 million (180), +197 percent to CER and Aspaveli®/Empaveli™ SEK 4 million (-)
  • Immunology revenue SEK 2,119m (1,554), +24% at constant exchange rates including Kineret® SEK 645 million (542), +11% at CER; Synagis® SEK 1,286 million (879), +31% at CER and Gamifant® 189M SEK (133), +27% at CER
  • EBITA1 SEK 1,290 million (1,484), EBITA margin1 26 for hundred (41)
  • Elements affecting comparability2 of -661 million SEK included a provision for expected credit losses Russia of -157 million SEK. The restructuring included the closure of the toll manufacturing of -360 MSEKsimplification of the site -72 million SEK and efficiency programs -72 million SEK. Excluding these costs, the Adjusted EBITA amounted to SEK 1,951 million corresponding to a Adjusted EBITA margin1 from 40 per hundred (41)
  • Efficiency programs focus resources on key areas, simplify the organization and adjust the cost base to enable Sobi to continue its sustainable growth and improved margins over time
  • EBIT SEK 776 million (1,034), Adjusted EBIT1 SEK 1,437 million (1,034)
  • Earnings per share (PES) before dilution SEK 1.84 (2.36), PES before adjusted dilution SEK 3.67 (2.36)
  • Cash flow operating activities SEK 1,644 M (1,699)
  • Efanesoctocog alfa positive reading from the XTEND-1 phase 3 study, gamifant approval in China and other encouraging pipeline milestones Outlook 2022
  • Revenue is expected to grow mid- to high-single digit at CER (unchanged)
  • EBITA margin should be at a low 30s percent of revenue (now based on EBITA adjusted margin)

Financial Summary


Q1

Q1


Full year

Full year


Full year

M SEK

2022

2021

Switch

2021

2020

Switch

2020

Total revenue

4,925

3,661

35%

15,529

15,261

2%

15,261

Gross profit

3,409

2,935

16%

12,045

12,036

0%

12,036

Gross margin1

69%

80%


78%

79%


79%

EBITA1

1,290

1,484

-13%

5,575

6,700

-17%

6,700

Adjusted EBITA1.2

1,951

1,484

31%

5,575

7,099

-21%

7,099

EBITA margin1

26%

41%


36%

44%


44%

Adjusted EBITA margin1.2

40%

41%


36%

47%


47%

Profit for the period

543

696

-22%

2,679

3,245

-17%

3,245

EPS, undiluted, SEK1

1.84

2.36

-22%

9.08

11.01

-18%

11.01

EPS, before dilution, adjusted in SEK1.2

3.67

2.36

55%

9.08

9.66

-6%

9.66

1Alternative Performance Measures (APM).

2Items affecting comparability in Q1 2022.

Investors, analysts and media are invited to participate in a conference call which will include an earnings presentation and a question-and-answer session at 1:00 p.m. CEST.

The presentation can be followed live here or afterwards on sobi.com. The slides will be available on sobi.com prior to the conference call.

To participate in the conference call, please call:

Sweden: +46 8 505 583 74 (direct)
UK: +44 3333 009 271 (direct)
USA: +1 631 913 1422 (toll) PIN: 27168016#

Sobi®

Sobi is a global specialty biopharmaceutical company transforming the lives of people with rare diseases. Providing sustainable access to innovative medicines in the fields of hematology, immunology and specialty care, Sobi has approximately 1,600 employees across Europe, North Americathe Middle East and Asia. In 2021, turnover amounts to 15.5 billion Swedish crowns. Sobi’s stock (STO:SOBI) is listed on Nasdaq Stockholm. More information about Sobi on sobi.com, LinkedIn and YouTube.

This information is information that Sobi is required to make public in accordance with the EU Market Abuse Regulation. The information has been submitted for publication, through the contact person listed below, to 08:00 CEST on April 28, 2022.

contacts

For information on how to contact Sobi’s Investor Relations team, please click here. For Sobi Media contacts, click here.

Thomas Kudsk Larsen

Communication and Investor Relations Manager

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/swedish-orphan-biovitrum-ab/r/sobi-publishes-q1-2022-report,c3554965

The following files are available for download:

SOURCE Swedish Orphan Biovitrum AB